investingdog, it's my view that the company will still need to manage and run it's trials. The issue I was addressing is how I feel about management, and, in the context of trial management, they will have the resources of one of the elite global pharm companies with which to coordinate.
I also don't think an acquisition is remotely likely. BP's have a pretty standard approach by now, and they acquire the rights to the proteins they want, from what I can tell. Much later, when/if PPHM has real products approved and there's more in the pipeline, then maybe there's an acquisition. But, for now, it's a deal for bavi, and bavi alone. But, the market isn't pricing that in at all.
News 
Market Data 
Discover 
